CyberKnife Lung Cancer Study | Phoenix CyberKnife Radiation & Oncology Center

LUNG CANCER STUDY

EFFECTIVENESS OF CYBERKNIFE SBRT/SABR TREATMENTS FOR STAGE I/II NON-SMALL CELL LUNG CANCER

The results of use of CyberKnife SBRT/SABR treatments for Stage I/II Non-Small Cell Lung Cancer, shown below, have compared favorably to surgery, both with regard to cure and complications.

STAGE I/II NSCLC RESULTS WITH HIGH DOSE SBRT/SABR

STUDY #PTS DOSE Fx SURV. F/U. COMPLICATIONS
Xia1 43 50 10 77% 3yrs 2%
Hof2 42 19-30 1 37% 3yrs 2%
Fakiris3 70 60-66 3 43% 3yrs 14%
Takeda4 63 50 5 76% 3yrs 5%
Ricardi5 196 48-60 3-8 68% 3yrs nr
Grills6 505 54 3 60% 2yrs 10%
Guckenberger7 582 54 3 47% 2yrs 7%
Shibamoto8 180 44-52 4 52% 5yrs 13-21%
Onishi9 87 45-72 3-10 67% 5yrs 1%
Timmerman10 59 54 3 56% 3yrs 16%
Stephans11 94 50-60 3-5 80% 1.5yrs 2%
Van der Voort12 70 45-60 3 62% 2yrs 13%
Uematsu13 50 50-60 5-10 66% 3yrs 0%
Zimmerman14 68 24-40 3-5 53% 3yrs 4%
Taremi15 108 50-60 3-10 77% 4yrs 0%
Baumann16 138 30-48 2-4 26% 5yrs 10%
Davis17 723 10-80 1-5 50% 2.5yrs nr
Koshy18 498 45-60 3-4 50% 3yrs nr
Rosen19 79 48-60 4-5 58% 3yrs 0%
Jeppesen20 100 45-66 3 50% 3yrs nr
Chang21 130 50 4 50% 5yrs 2.3%
Senthi22 676 54-60 3-8 57% 5yrs nr
Lagerwaard23 382 60 3-8 50% 3.5yrs nr
Hiraoka24 241 48 4 44% 5yrs nr
Chang@25 58 50 5 95%(SBRT) 3yrs 10%
79%(Surgery) 3yrs 48%
p<0.05 p <0.05

*Cause specific survival

@Randomized Trial

Most of the work outlined above has been pioneered in Europe and Japan. The last study in the table above by Chang et al, (Lancet, 2015) is the first randomized trial to compare SBRT/SABR to the historical standard of surgery. The randomized trial is the gold standard in medicine to judge results with different treatments. Dr. John Kresl, the Medical Director of the Phoenix CyberKnife Center and leading pioneer in the field of SBRT/SABR, is a co-author on the landmark randomized trial paper discussed above. The Phoenix CyberKnife Center has been offering the state-of-the-art CyberKnife SBRT/SABR treatments to its patients for XX years.

In the studies, SBRT/SABR proved superior to surgery in regard to survival. Complications also were markedly less. In the SBRT/SABR group, 10 percent of patients had grade 3 complications, which included chest wall pain, cough, shortness of breath, fatigue, and one case, rib fracture. There were no grade 4 (death) complications. In the surgery group, 48 percent of patients experienced grade 3 or 4 complications, including 4 percent of patients who died. SBRT/SABR in contrast to surgery, is a painless non-invasive procedure, done entirely as an outpatient in five days, with each treatment taking about 30 minutes to deliver.

These results compare very favorable to modern day surgical sleeve lobectomy for clinical Stage I/II NSCLC, which are outlined in the following studies:

STAGE I/II NSCLC RESULTS WITH SURGICAL SLEEVE LOBECTOMY

AUTHOR #PTS SURVIVAL F/U MORTALITY
Park26 157 58.4% 5yrs 1.0%
Van Schil27 145 49% 5yrs 4.8%
Rea28 199 39.7% 5yrs 4.5%
De Leyn29 77 45.6% 5yrs 3.9%
Ludwig30 116 39% 5yrs 4.3%
Merritt31 196 44% 5yrs 2.0%
Tronc32 184 52% 5yrs 1.6%
Fadel33 169 52% 5yrs 2.9%
Yildizeli34 218 53% 5yrs 4.1%
Deslauriers35 184 52% 5yrs 1.6%
Martini36 511* 75% 5yrs 2.3%
*All Stage I NSCLC

References :

  1. Xia T, et al. Promising Clinical Outcome of Stereotactic Body Radiation Therapy for Patients with Inoperable Stage I/II Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys, 2006 ; 66[1]:117.
  2. Hof H, et al. Stereotactic Single Dose Radiotherapy (Radiosurgery) of Early Stage Non-Small Cell Lung Cancer. Cancer, 2007 ; 110[1]:148.
  3. Fakiris AJ, el al. Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer : Four Year Results of a Prospective Phase II Study. Int J Radiat Oncol Biol Phys, 2009 ; 75[3]:677.
  4. Takeda A, et al. Stereotactic Body Radiation Therapy for Primary Lung Cancer at a Dose of 50 Gy Total in 5 Fractions to the Periphery of the Planning Target Volume Using a Superposition Algorithm. Int J Radiat Oncol Biol Phys, 2009 ; 73 [2] : 442.
  5. Ricardi U, et al. Stereotactic Body Radiation Therapy for Stage I Histologically Proven Non-Small Cell Lung Cancer : An Italian Multi-Center Observational Study. Lung Cancer, 2014 ; 84[3] :248.
  6. Grills IS, et al. A Collaborative Analysis of Stereotactic Body Radiation Therapy Outcomes for Early Stage Non-Small Cell Lung Cancer Using Daily On-Line Cone Beam CT Image Guide Radiation Therapy. J Thorac Oncol, 2012 ; 7[9]:1382.
  7. Guckenberger M, et al. Safety and Efficacy of Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer in Routine Clinical Practice : A Patterns of Care and Outcome Analysis. J Thorac Oncol, 2013 ; 8[8]:1050.
  8. Shibamato Y, et al. Stereotactic Body Radiation Therapy Using a Radiology Based Regimen for Stage I Non-Small Cell Lung Cancer : Five Year Mature Results. J Thorac Oncol, 2015 ; 10[6]:960.
  9. Onishi H, et al. Stereotactic Body Radiation Therapy for Operable Stage I Non-Small Cell Lung Cancer : Can Stereotactic Body Radiation Therapy be Comparable to Surgery? Int J Radiat Oncol Biol Phys, 2011 ; 81[5]:1352.
  10. Timmerman R, et al. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. JAMA, 2010 ; 303[11]:1070.
  11. Stephens KL, et al. A Comparison of Two Stereotactic Body Fractionation Schedules for Medically Inoperable Stage I Non-Small Cell Lung Cancer. The Cleveland Clinic Experience. J Thorac Oncol, 2009 ; 4[8]:976.
  12. Van der Voort van Zyp NC, et al. Stereotactic Radiotherapy with Real-Time Tumor Tracking for Non-Small Cell Lung Cancer : Clinical Outcome. Radiother Oncol, 2009 ; 91[3]:296.
  13. Uematsu M, et al. CT Guided Frameless Stereotactic Radiotherapy for Stage I Non-Small Cell Lung Cancer : A Five Year Experience. Int J Radiat Oncol Biol Phys, 2001 ; 51[3]:666.
  14. Zimmerman FB, et al. Stereotactic Hypofractionated Radiotherapy in Stage I (T1-2,N0,M0) Non-Small Cell Lung Cancer. Acta Oncol, 2006 ; 45[7]:796.
  15. Taremi M, et al. Stereotactic Body Radiation Therapy for Medically Inoperable Lung Cancer : Prospective Single Center Study of 108 Consecutive Patients. Int J Radiat Oncol Biol Phys, 2012 ; 82[2]:967.
  16. Baumann P, et al. Factors Important for Efficacy of Stereotactic Body Radiation Therapy for Medically Inoperable Stage I Lung Cancer : A Retrospective Analysis of Patients Treated in the Nordic Countries. Acta Oncol, 2006 ; 45[7]:787.
  17. Davis JN, et al. Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer : Clinical Outcomes from a National Patient Registry. J Radiat Oncol, 2015 ; 4[1]:55.
  18. Koshy M, et al. Increasing Radiotherapy Dose is Associated with Improve Survival in Patients undergoing Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys, 2015 ; 91[2]:344.
  19. Rosen JR, et. Helical Image Guided Stereotactic Body Radiation Therapy for the Treatment of Early Stage Lung Cancer : A Single Institution Experience at the Willis-Knighton Cancer Center. Tumori, 2014 ; 100[1]:42.
  20. Jeppesen SS, et al. Stereotactic Body Radiation Therapy vs. Conventional Radiation Therapy in patient with Early Stage Non-Small Cell Lung Cancer : An Updated Retrospective Study on Local Failure and Survival Rates. Acta Oncol, 2013 ; 52[7]:1552.
  21. Chang JY, et al. Clinical Outcome and Predictors of Survival and Pneumonitis after Stereotactic Ablative Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Radiat Oncol, 2012 ; 10[7]:152.
  22. Senthi S, et al. Patterns of Disease Recurrence after Stereotactic Ablative Radiation Therapy for Early Stage Non-Small Cell Lung Cancer : A Retrospective Analysis. Lancet Oncol, 2012 ; 13[8]:802.
  23. Lagerwaard FJ, et al. Patient Reported Quality of Life after Stereotactic Ablative Radiation Therapy for Early Stage Lung Cancer. J Thorac Oncol, 2012 ; 7[7]:1148.
  24. Hiraoka M, et al. Stereotactic Body Radiation Therapy for Early Stage Lung Cancer. Cancer Radiother, 2007 ; 11[1]:32.
  25. Chang JY, et al. Stereotactic Body Radiation Therapy vs. Lobectomy for Operable Stage I Non-Small Cell Lung Cancer : A Pooled Analysis of Two Randomized Trials. Lancet Oncol, 2015 ; 16[6]:630.
  26. Park JS, et al. Sleeve Lobectomy as an Alternative Procedure to Pneumonectomy for Non-Small Cell Lung Cancer. J Thorac Oncol, 2010 ; 5[4]:517.
  27. Van Schill PE, et al. TNM Staging and Long-Term Follow-up After Sleeve Resection for Bronchogenic Tumors. Ann Thorac Surg, 1991 ; 52[5]:1096.
  28. Rea F, et al. A Quarter of a Century Experience with Sleeve Lobectomy for Non-Small Cell Lung Cancer. Eur J Cardiothorac Surg, 2008; 34[3]:488.
  29. De Leyn P, et al. Sleeve Lobectomy for Non-Small Cell Lung Cancer. Acta Chir Belg, 2003 ; 103[6]:570.
  30. Ludwig C, et al .Comparison of Morbidtiy, 30 day Mortality, and Long-Term Survival after Pneumonectomy and Sleeve Resection for Non-Small Cell Lung Cancer. Ann Thorac Surg, 2005 ; 79[3]:968.
  31. Merritt RE, et al. Long-Term Results of Sleeve Lobectomy in the Management of Non-Small Cell Lung Cancer and Low Grade Neoplasms. Ann Thorac Surg, 2009 ; 88[5] : 1574.
  32. Tronc F, et al. Long-Term Results of Sleeve Lobectomy for Lung Cancer. Eur J Cardiothorac Surg, 2000 ; 17[5]:550.
  33. Fadel E, et al. Sleeve Lobectomy for Bronchogenic Carcinomas : Factors Affecting Survival. Ann Thorac Surg, 2002 ; 74[3]:851.
  34. Yildizeli B, et al. Morbidity, Mortality, and Long-Term Survival After Sleeve Lobectomy for Non-Small Cell Lung Cancer. Eur J Cardiothorac Surg, 2007 ; 31[1]:95.
  35. Deslauriers J, et al. Sleeve Lobectomy vs. Pneumonectomy for Lung Cancer : A Comparative Analysis of Survival and Sites of Recurrences. Ann Thorac Surg, 2004; 77[4]:1152.
  36. Martini N, et al. Incidence of Local Recurrence and Second Primary Tumors in Resected Stage I Lung Cancer. J Thorac Cardiovasc Surg, 1995 ; 109[1]:120.
CONTACT US

COVID-19 UPDATE

Our top priority is the health and safety of our patients. Treatments will continue as our staff is taking extra precautionary measures to ensure the safety of all patients. We are working closely with local and national health authorities to stay informed on all important developments.

Contact our office prior to your appointment.

Phoenix Cyberknife Radiation Oncology is dedicated to the health and safety of our employees, patients, and their families. With the recent spread of COVID-19 and the height of cold and flu season, it is important to be mindful of not only yourself but others around you as well. These viruses are spread from person to person through coughing, sneezing, contact with contaminated surfaces and close personal contact. If you are experiencing any of the following symptoms: runny nose, dry cough, low-grade fevers or shortness of breath; please contact our office prior to your appointment for further instruction

Click here for more information for the Arizona Department of Health Services.